lol
CYP has a big boy competitor in the DFU space but not many on here want to recognise that ....
another Aussie biotech is undertaking an FDA approved RCT trial almost 5 times the size of CYP's for DFU's in multiple USA sites (8) .... meanwhile Ross is happy to announce today that the DSMB has completed an interim assessment on the
30 patient trial in Australia without disclosing any recruitment numbers as a big deal market sensitive announcement ... like you said
@Pledge most likely a KPI ticked off right before the AGM .... LMAO
Here's a snippet from the 10 August 2022 announcement without disclosing the company name... I wouldn't want people to think my post was a cross promotion; especially given I don't hold the stock ?
The randomised control trial (RCT) on 138 subjects focuses on the use of SynPath to treat chronic diabetic foot ulcers. Given the number of people with Diabetes and the number of DFU patients, recruitment is anticipated to be completed by April 2023. The trial is being conducted over eight sites in the US including The Center for Clinical Research Inc., San Francisco, California and Barry University, Miami, Florida. The primary efficacy endpoint is to measure the percentage of ulcers fully healed at 12 weeks.
Based on a number of factors I would imagine this other Aussie biotech will trump anything CYP come up with and probably finish the trial earlier given CYP received ethics approval for the DFU trial in June 2021 - almost 18 months ago and they still haven't recruited a measly 30 participants .... but hey they are half way there if you take anything Hector Projector claims today as gospel .... LMAO
(20min delay)